Researchers have identified a protein critical for the survival of a particular type of tumour cell, according to a study published today in the journal eLife.
The findings suggest that targeting a protein called Werner syndrome helicase (WRN) could represent a novel opportunity for treating a subgroup of cancer patients with microsatellite instability-high (MSI-H) tumours.
MSI is a clinically defined characteristic of cancer cells that harbour defects in DNA mismatch repair (MMR), which is the system for fixing errors that can occur during DNA replication.
Defective MMR and MSI-H are observed in approximately 4 percent of all cases of human cancer, with particularly high prevalence in colorectal, endometrial and gastric cancers.
Treatment for MSI-H tumours has shifted recently with the approval of the immunotherapies pembrolizumab, nivolumab and ipilimumab.
But while these drugs often lead to long-lasting positive responses in MSI-H cancer patients, eventual resistance to immunotherapy means there is still a need for more effective treatments.
“Targeted cancer therapy is based on exploiting the biological systems that tumour cells, but not healthy tissues, rely on for survival,” said senior author Simon Wöhrle, Principal Scientist at Boehringer Ingelheim Regional Center Vienna (RCV), Austria.
“Before we can develop new treatments against MSI-H cancer cells, we first need to understand what it is that helps them to survive and thrive.”
The team used MSI-H cancer-cell profiling and recent functional screening data of cell lines to help answer this question.
They demonstrated that removing the function of WRN from MSI-H cells prevented them from working properly and caused defects in cell division.
“In particular, we saw that WRN-depleted MSI-H cancer cell lines displayed chromosome breaks and genome instability, highlighting WRN as a novel vulnerability of MSI-H cells,” explained co-senior author Mark Petronczki, Director Cancer Cell Signaling at Boehringer Ingelheim RCV.
As WRN loss is known to cause Werner syndrome, a premature ageing disease associated with an increased lifetime risk of developing tumours, it has previously been suggested that the protein plays a key role in suppressing tumours.
However, in contrast to this idea, the current results show that WRN possesses a striking pro-survival function for specific cancer cells.
“We’ve shown the power of combining deep functional genomic screen data with tumour cell-line profiling to identify new targets in oncology,” concluded co-senior author Mark Pearson, Vice President at Boehringer Ingelheim RCV. “Our results indicate that pharmacological inhibition of WRN function might serve as a novel targeted therapeutic strategy in MSI-H cancer to help meet the demand for more effective drugs.”